EA201890816A1 - Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) - Google Patents
Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)Info
- Publication number
- EA201890816A1 EA201890816A1 EA201890816A EA201890816A EA201890816A1 EA 201890816 A1 EA201890816 A1 EA 201890816A1 EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A1 EA201890816 A1 EA 201890816A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mcrpc
- castration
- prostate cancer
- metastatic prostate
- patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233206P | 2015-09-25 | 2015-09-25 | |
| PCT/US2016/053387 WO2017053763A2 (en) | 2015-09-25 | 2016-09-23 | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890816A1 true EA201890816A1 (ru) | 2018-09-28 |
Family
ID=58387342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890816A EA201890816A1 (ru) | 2015-09-25 | 2016-09-23 | Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190285636A1 (https=) |
| EP (1) | EP3353553B1 (https=) |
| JP (1) | JP6936231B2 (https=) |
| CN (3) | CN118443943A (https=) |
| AU (1) | AU2016325617A1 (https=) |
| CA (1) | CA2999911A1 (https=) |
| EA (1) | EA201890816A1 (https=) |
| IL (1) | IL258318A (https=) |
| WO (1) | WO2017053763A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101926117B1 (ko) * | 2017-08-18 | 2018-12-06 | 주식회사 싸이토젠 | 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 |
| CN113905729A (zh) * | 2019-03-28 | 2022-01-07 | 凯帝夫肿瘤科技有限公司 | Plk1抑制剂和前列腺癌中的psa水平 |
| JP2023534375A (ja) * | 2020-05-28 | 2023-08-09 | 王 道祥 | 細胞病理学的サンプルに対する多重染色切片調製法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| WO2015048740A1 (en) * | 2013-09-30 | 2015-04-02 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| US10527624B2 (en) * | 2014-01-27 | 2020-01-07 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| US20150212089A1 (en) * | 2014-01-30 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-09-23 CA CA2999911A patent/CA2999911A1/en not_active Abandoned
- 2016-09-23 EP EP16849728.7A patent/EP3353553B1/en active Active
- 2016-09-23 AU AU2016325617A patent/AU2016325617A1/en not_active Abandoned
- 2016-09-23 EA EA201890816A patent/EA201890816A1/ru unknown
- 2016-09-23 CN CN202410551103.0A patent/CN118443943A/zh active Pending
- 2016-09-23 CN CN202410551097.9A patent/CN118443942A/zh active Pending
- 2016-09-23 JP JP2018536062A patent/JP6936231B2/ja active Active
- 2016-09-23 WO PCT/US2016/053387 patent/WO2017053763A2/en not_active Ceased
- 2016-09-23 CN CN201680068025.2A patent/CN108450001A/zh active Pending
- 2016-09-23 US US15/762,076 patent/US20190285636A1/en not_active Abandoned
-
2018
- 2018-03-22 IL IL258318A patent/IL258318A/en unknown
-
2023
- 2023-02-27 US US18/175,427 patent/US20240036047A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108450001A (zh) | 2018-08-24 |
| US20240036047A1 (en) | 2024-02-01 |
| WO2017053763A3 (en) | 2017-12-21 |
| JP6936231B2 (ja) | 2021-09-15 |
| EP3353553A4 (en) | 2019-04-17 |
| CN118443942A (zh) | 2024-08-06 |
| IL258318A (en) | 2018-05-31 |
| AU2016325617A1 (en) | 2018-04-19 |
| CA2999911A1 (en) | 2017-03-30 |
| WO2017053763A2 (en) | 2017-03-30 |
| US20190285636A1 (en) | 2019-09-19 |
| CN118443943A (zh) | 2024-08-06 |
| JP2018535432A (ja) | 2018-11-29 |
| EP3353553A2 (en) | 2018-08-01 |
| EP3353553B1 (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harouaka et al. | Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications | |
| Criscitiello et al. | Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer | |
| EA201691505A1 (ru) | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) | |
| EA201891571A1 (ru) | Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| EA201691496A1 (ru) | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX392671B (es) | Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| Zhang et al. | Negative prognostic impact of low absolute CD 4+ T cell counts in peripheral blood in mantle cell lymphoma | |
| MX375794B (es) | Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. | |
| EA201891085A1 (ru) | Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| MX2018009254A (es) | Metodos para evaluar el riesgo de desarrollar cancer colorrectal. | |
| EA201890816A1 (ru) | Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) | |
| MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
| PH12019500675A1 (en) | Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer | |
| EA201691497A1 (ru) | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток | |
| GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| Del Gobbo et al. | The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas |